Iqvia provides services and technology to the life sciences industry, helping drug, biotech and medical device companies plan and run clinical trials, analyse health data and bring products to market. Its customers include pharmaceutical and biotechnology firms, medical device makers and healthcare organisations. The company is organised around technology and analytics solutions, research and development solutions, and contract sales and medical solutions, drawing on large stores of healthcare data.
Revenue comes from multi-year research contracts and from data, analytics and technology services supplied to life sciences clients. It totals $16.6 billion over the last twelve months, growing at 4.2% a year across the last three years. The operating margin is 13.2%, and the business earns a profit of 9% on the capital invested in it. Iqvia carries net debt of 4.1 times EBITDA and does not pay a dividend. On the site's X-Ray Score it receives 42 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
52-wk range $154.50 – $277.40Volume 1,037,000Daily, split-adjusted
Vitals
Market cap$45.3B
52-week range$154.50 – $277.40
Volume (last day)1,037,000
P/E (TTM)33.2
EBIT / EV yield3.7%
Free-cash-flow yield4.7%
Dividend yieldNo dividend
Revenue (TTM)$16.6B
Net income (TTM)$1.4B
Operating margin13.2%
Return on capital9.3%
Debt incl. leases$15.8B
Cash & securities$2.1B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$200model spread $190 – $211
Overvalued−25.0% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is Medium, so the safety margin is 30%.
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Weak business, priced high
Our models put fair value below today's price, so a lot of good news may already be in the price. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
ValuationWeak
44/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield3.7%
Free-cash-flow yield4.7%
Fair value vs price0.8×
GrowthFair
56/100
Growing at a typical pace for its sector.
See the numbers →
Revenue growth (3y)4.2%
EPS growth (3y)11.1%
Growth consistency100%
ProfitabilityFair
52/100
Returns on capital are typical for its sector.
See the numbers →
Return on invested capital9.3%
Operating margin13.2%
Financial healthWeak
11/100
Balance sheet is more stretched than most peers.
See the numbers →
Piotroski F-Score4 / 9
Net debt / EBITDA4.1×
Interest cover2.9×
DividendsNone
–/100
Pays no dividend.
See the numbers →
Quarterly results: last 6 quarters
+2.3%Dec '24
+2.5%Mar '25
+5.3%Jun '25
+5.2%Sep '25
+10.3%Dec '25
+8.4%Mar '26
Revenue against the same quarter a year earlier. Latest quarter revenue $4.2B, diluted EPS $1.61.
Other Life Sciences Tools & Services companies by X-Ray Score.
Fundamentals checklist
● 1 Good · ● 9 Average · ● 5 Bad
Cash quality
Earnings backed by cashAverage
Free-cash-flow yieldAverage
Risk models
Altman Z''Bad
Piotroski F-ScoreBad
Growth
EPS growth (3y)Average
Free-cash-flow growth (3y)Average
Revenue growth (3y)Average
Growth consistencyGood
Balance sheet
Current ratioBad
Net debt / EBITDABad
Interest coverBad
Valuation
Fair value vs priceAverage
EBIT / EV yieldAverage
Profitability
Return on invested capitalAverage
Operating marginAverage
Each check is graded against the company's sector, not a fixed number. Checklist score 41/100.
Financials
FY21
FY22
FY23
FY24
FY25
Revenue
$13.9B
$14.4B
$15.0B
$15.4B
$16.3B
Operating income
$1.4B
$1.8B
$2.0B
$2.2B
$2.2B
Net income
$966M
$1.1B
$1.4B
$1.4B
$1.4B
Operating cash flow
$2.9B
$2.3B
$2.1B
$2.7B
$2.7B
Operating margin
10.0%
12.5%
13.2%
14.3%
13.4%
Free cash flow
$2.3B
$1.6B
$1.5B
$2.1B
$2.1B
Diluted EPS
$4.95
$5.72
$7.29
$7.49
$7.84
Fiscal years, from SEC filings.
Technical summary
Daily
Strongly bullish
11 bullish · 4 neutral · 1 bearish
Weekly
Strongly bullish
11 bullish · 1 neutral · 0 bearish
Monthly
Strongly bullish
7 bullish · 1 neutral · 0 bearish
Moving averages (daily)
SMA 10
262.6
Bullish
EMA 10
264.2
Bullish
SMA 20
265.3
Bullish
EMA 20
263.8
Bullish
SMA 50
260.0
Bullish
EMA 50
255.0
Bullish
SMA 100
229.6
Bullish
EMA 100
237.4
Bullish
SMA 200
207.7
Bullish
EMA 200
219.7
Bullish
Oscillators (daily)
RSI (14)
54.79
Neutral
MACD (12, 26)
1.29
Bullish
Momentum (12)
-0.73
Bearish
Stochastic %K (14)
66.02
Neutral
Williams %R (14)
-33.98
Neutral
CCI (20)
32.56
Neutral
Pivot points (classic, last session)
S3
252.6
S2
257.9
S1
262.4
Pivot
267.7
R1
272.2
R2
277.5
R3
282.0
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.